Mitiglinide calcium hydrate

Drugs of the Future

Volumn 25, Issue 10, 2000, Pages 1034-1042

  Sorbera, L A ^a   Leeson, P A ^a   Castaner, R M ^a   Castaner, J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; IMIDAZOLE DERIVATIVE; MITIGLINIDE; NATEGLINIDE; PHENETHYLAMINE DERIVATIVE; REPAGLINIDE; SUCCINIMIDE DERIVATIVE; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SIDE EFFECT;

EID: 0033635595     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.10.598279     Document Type: Review

References (36)

1. Preparation of optically active succinic acid derivatives I. Optical resolution of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid
2. Preparation of optically active succinic acid derivatives. II. Efficient and practical synthesis of KAD-1229
3. Synthesis of KAD-1229, a succinic acid derivative with optical activity
4. Synthesis of KAD-1229, a succinic acid derivative with optical activity (1)
5. Preparation of optically active succinic acid derivatives. III. Regioselective condensation reactions of optically active 2-substituted succinic acids with diimidazolide
6. The worldwide burden of diabetes
7. Clinical pharmacology of sulphonylurea hypoglycaemic agents: Part 1
8. Clinical pharmacology of sulphonylurea hypoglycaemic agents: Part 2
9. Incidence of severe side effects during therapy with sulfonylureas and biguanides
10. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents
11. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family
12. Dissociation between the potency and reversibility of the insulinotropic action of two meglitinide analogues
13. Mechanism of action of a new class of insulin secretagogues
14. Novel rapid- and short-acting hypoglycemic agent, a calcium(2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: Comparison of effects between KAD-1229 and gliclazide
15. + channel by a non-sulfonylurea compound KAD-1229 in a pancreatic betacell line, MIN 6 cell
16. Ionophoretic properties of the non-sulfonylurea hypoglycemic agents A-4166 and KAD-1229
17. Effects of ATP and hypoglycaemic agents on 45Ca uptake by subcellular fractions prepared from rat pancreatic islets
18. Effect of the meglitinide analogue KAD-1229 on 45Ca outflow and insulin release in pancreatic islets
19. + concentrations
20. 2+-induced insulin release
21. In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2S)-2-benzyl-3-(cis-hexahydro-2isoindolinyl-carbonyl) propionate dihydrate (KAD-1229), in rat pancreatic β-cells
22. Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate. I. Secretory and cationic aspects
23. Effect of the meglitinide analog S21403 on cationic fluxes and insulin release in perifused rat pancreatic islets exposed to a high concentration of D-glucose
24. Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat
25. Effect of a novel hypoglycemic agent, KAD-1229 on glucose metabolism and fructose-2,6-bisphos phate content in isolated hepatocytes of normal rats
26. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats
27. Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in noninsulin-dependent diabetes mellitus rats
28. - channels by non-sulphonylurea hypoglycaemic agents
29. Hypoglycemic effects and safety of a novel rapid-acting insulinotropic agent, KAD-1229, for NIDDM